These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6329121)

  • 21. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study.
    Matsunaga T; Ohyama S; Takehara S; Kabashima K; Moriyama S; Tsuzuki J; Ikeda H; Suematsu M; Akizuki K; Fujimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):533-9. PubMed ID: 3043555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical study on the psychotropic effects of caerulein--an open clinical trial in chronic schizophrenic patients.
    Itoh H; Tanoue S; Yagi G; Tateyama M; Kamisada M; Fujii Y; Takamiya M; Nakajima S
    Keio J Med; 1982 Oct; 31(3):71-95. PubMed ID: 6764226
    [No Abstract]   [Full Text] [Related]  

  • 24. Cholecystokinin peptides, dopamine and schizophrenia--a review.
    Nair NP; Lal S; Bloom DM
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceruletide, ceruletide analogues and cholecystokinin octapeptide (CCK-8): effects on motor behaviour, hexobarbital-induced sleep and harman-induced convulsions.
    Zetler G
    Peptides; 1982; 3(4):701-4. PubMed ID: 6291014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of schizophrenia with a vasopressin analogue.
    Iager AC; Kirch DG; Bigelow LB; Karson CN
    Am J Psychiatry; 1986 Mar; 143(3):375-7. PubMed ID: 3513631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
    Saletu B; Küfferle B; Grünberger J; Földes P; Topitz A; Anderer P
    Neuropsychobiology; 1994; 29(3):125-35. PubMed ID: 7912819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
    Grebb JA; Shelton RC; Taylor EH; Bigelow LB
    Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
    [No Abstract]   [Full Text] [Related]  

  • 32. Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.
    Emrich HM; Zaudig M; Kissling W; Dirlich G; von Zerssen D; Herz A
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Sep; 13(5):290-8. PubMed ID: 7003611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia.
    Goff DC; Amico E; Dreyfuss D; Ciraulo D
    Am J Psychiatry; 1994 Mar; 151(3):429-31. PubMed ID: 8109654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.
    Csernansky JG; Riney SJ; Lombrozo L; Overall JE; Hollister LE
    Arch Gen Psychiatry; 1988 Jul; 45(7):655-9. PubMed ID: 3289523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
    Kramer MS; Last B; Getson A; Reines SA
    Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
    Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
    Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.
    Wolkowitz OM; Pickar D; Doran AR; Breier A; Tarell J; Paul SM
    Am J Psychiatry; 1986 Jan; 143(1):85-7. PubMed ID: 2867690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine.
    Prusoff BA; Williams DH; Weissman MM; Astrachan BM
    Arch Gen Psychiatry; 1979 May; 36(5):569-75. PubMed ID: 373665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central effects of ceruletide analogues.
    Zetler G
    Peptides; 1981; 2 Suppl 2():65-9. PubMed ID: 6283499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.